But for moderate to severe plaque psoriasis, therapeutic advancements include biologics such as TNF-α, IL-12/23, IL-17, and IL-23, as well as an oral phosphodiesterase 4 inhibitor. The gene discussed is TNF; the disease is psoriasis vulgaris.